secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-07-22T12:14:47+00:00
Accession:  0001193125-26-311357
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharma accelerates Phase 3 NOVA-2 topline to H1 2027; cash runway into Q2 2029
--------------------------------------------------------------------------------

- Topline results from Phase 3 NOVA-2 trial of LB-102 in schizophrenia now expected in first half of 2027, ahead of prior guidance.
- Pre-NDA meeting with FDA scheduled for second half of 2027.
- Cash runway expected to fund operations into Q2 2029 through multiple clinical readouts.
- Phase 2 ILLUMINATE-1 trial in bipolar depression topline expected in Q1 2028.
- Phase 2 trial of LB-102 in adjunctive MDD topline expected in first half of 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/0001193125-26-311357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526311357/d173035d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-311357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer